Phase 1 and Other Cancers
The following list provides a brief description of Phase 1 and other cancer trials that are open for recruitment in Western Australia. If you would like more information please follow the links provided, contact one of the trial sites or speak with your doctor.
Please note that this list is based on information provided to the Cancer Council by WA hospitals and may not include all clinical trials that are running in WA.
Where ‘N/A' appears - this means the lacking information has not been provided to date to the Cancer Council.
Denosumab study
|
Registered Title |
An Open-label, Multi-Centre, Phase 2 Study of Denosumab in Subjects with Giant Cell Tumour of Bone. |
|
Purpose |
To determine how safe denosumab is in treating subjects with giant cell tumor of bone. |
|
Lay Summary |
N/A |
|
WA Trial Sites |
SCGH Medical Oncology |
|
Links |
Acknowledgements: US National Library of Medicine
FAK113517 Study
|
Registered Title |
Phase I, Open-Label, Dose Escalation Study of FAK inhibitor GSK2256098 in Subjects with Solid Tumours. |
|
Purpose |
The primary objective of this study is to determine the safety, tolerability, and MTD of GSK2256098. Secondary objectives are to characterize the pharmacokinetics (PK) of GSK2256098; to identify a range of biologically active doses; to explore the anti-tumor activity of GSK2256098, and to explore relationships between GSK2256098 PK, PD and clinical endpoints.
This study is a Phase I dose escalation study in subjects with solid tumors. Part 1 will identify the maximum tolerated dose (MTD) using a dose-escalation procedure. Following identification of the MTD, enrollment into Parts 2, 3 and 4 may be concurrent.
Part 2 will explore further the safety, PK, tolerability, and anti-tumor activity of GSK2256098 in subjects with tumors known to overexpress focal adhesion kinase (FAK).
Part 3 will characterize the range of biologically effective doses by assessing pharmacodynamic (PD) markers in hair, skin and tumor tissue at doses that will not go lower than 80 mg or above the MTD dose levels tested during the Phase 1 dose escalation.
Part 4 will explore further the safety, PK, tolerability and anti-tumor activity of GSK2256098 in subjects with relapsed glioblastoma multiforme (GBM). |
|
Lay Summary |
N/A |
|
WA Trial Sites |
Linear Clinical Research Ltd |
|
Links |
Acknowledgements: US National Library of Medicine
IMRT
|
Registered Title |
Intensity modulated radiotherapy prospective data collection information. |
|
Purpose |
To evaluate the intensity modulated radiotherapy (IMRT) technique of treating cancers. |
|
Lay Summary |
The primary aim of the data collection study is to document the local recurrence rates, patterns of recurrence and overall survival rates for those treated with IMRT.
Another important outcome of the study is the documentation of both acute and late toxicity of this treatment.
The results of the IMRT treatment program may be published in a peer-reviewed journal, where non identifying information will be used. |
|
WA Trial Sites |
Perth Radiation Oncology Centre |
|
Links |
N/A |
Linear Sarcoma
|
Registered Title |
Phase 1 Study of BMS-754807 in Subjects with advanced or metastatic solid tumours. |
|
Purpose |
This is a Phase 1 dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of BMS-754807 in patients with advanced or metastatic solid tumors. In addition, the study is expected to identify the recommended dose or dose range of BMS-754807 for Phase 2 studies |
|
Lay Summary |
N/A |
|
W Trial Sites |
Linear Clinical Research Ltd |
|
Links |
Acknowledgements: US National Library of Medicine
Picasso III
|
Registered Title |
A Phase III Multicenter, International, Randomised, Double-blind, Placebo-controlled Study of Doxorubicin plus Palifosfamide-tris vs. Doxorubicin plus Placebo in Patients with Front-line Metastatic Soft Tissue Sarcoma. |
|
Purpose |
This is an international, randomized, double-blind, placebo-controlled trial to evaluate the clinical efficacy of palifosfamide-tris administered with doxorubicin in combination, compared with doxorubicin administered with placebo in front-line patients diagnosed with metastatic soft tissue sarcoma (STS). |
|
Lay Summary |
N/A |
|
WA Trial Sites |
SCGH Medical Oncology |
|
Links |
Acknowledgements: US National Library of Medicine
[Return to List of Clinical Trials]
